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Domain interactionFamilial hemiplegicmigraine (FHM) is a monogenic variant ofmigrainewith aura. One of the three known caus-
ative genes, ATP1A2, which encodes the α2 isoform of Na,K-ATPase, causes FHM type 2 (FHM2). Over 50 FHM2
mutations have been reported, but most have not been characterized functionally. Here we study the molecular
mechanism of Na,K-ATPaseα2 missense mutations. Mutants E700K and P786L inactivate or strongly reduce en-
zyme activity. Glutamic acid 700 is located in the phosphorylation (P) domain and the mutation most likely dis-
rupts the salt bridge with Lysine 35, thereby destabilizing the interaction with the actuator (A) domain. Mutants
G900R and E902K are present in the extracellular loop at the interface of theα andβ subunit. Bothmutants likely
hamper the interaction between these subunits and thereby decrease enzyme activity. Mutants E174K, R548C
and R548H reduce the Na+ and increase the K+ afﬁnity. Glutamic acid 174 is present in the A domain and
might form a salt bridge with Lysine 432 in the nucleotide binding (N) domain, whereas Arginine 548, which
is located in the N domain, forms a salt bridge with Glutamine 219 in the A domain. In the catalytic cycle, the in-
teractions of the A and N domains affect the K+ and Na+ afﬁnities, as observed with these mutants. Functional
consequences were not observed for ATP1A2 mutations found in two sporadic hemiplegic migraine cases
(Y9N and R879Q) and in migraine without aura (R51H and C702Y).
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Migraine is a disabling common brain disorder typically character-
ized by attacks of severe headache and associated with autonomic and
neurological symptoms [1]. Auras that consist of transientmainly visual
and sensory symptoms can precede headaches in one-third of patients
(hence migraine with aura). Auras are likely caused by cortical spread-
ing depression (CSD) events, which are slowly propagating cortical
waves of neuronal and glial depolarization [2]. Familial hemiplegic mi-
graine (FHM) is a rare monogenic variant of migraine with aura with
some degree of hemiparesis during the aura [1]. Of the three known
FHM genes, two encode α1 subunits of voltage-gated CaV2.1 calcium
channels (CACNA1A; FHM1) or voltage-gated NaV1.1 sodium channels
(SCN1A; FHM3) [3–5]. ATP1A2 (FHM2) encodes the catalyticα2 subunit
of the sodiumpotassiumpump [6]. This pump transfers Na+ out and K+31 24 3614214.
s),
aar@ncmls.ru.nl (H. Venselaar),
n Maagdenberg),
@pharmtox.umcn.nl
ights reserved.into the cell, using ATP as energy source. The sodium pump is present in
all human cells, but the α2 isoform is mainly restricted to brain and
muscle. In the adult brain α2 is located in glial cells where it generates
the Na+ gradient that is essential for the re-uptake of the excitatory
transmitter glutamate.Moreover, it also removes excess K+ from the in-
tracellular space [7].
Since the discovery of the ﬁrst FHM2 mutation in 2003 [6], over 50
ATP1A2 mutations have been published, but only a minority have
been functionally studied in detail [7]. ATP1A2mutations have been re-
ported to be associated also with non-FHM phenotypes such as basilar
migraine, alternating hemiplegia of childhood, and common migraine
with orwithout aura [7]. Formost of themutations, however, functional
evidence supporting that these mutations are causal is lacking. Here we
set out to investigate ATP1A2 mutations associated with FHM and non-
FHM phenotypes in an attempt to ﬁnd functional evidence for an asso-
ciation with a broader spectrum of migraine-related phenotypes. In ad-
dition,we investigatedwhether some of themutationsmay be involved
in speciﬁc domain interactionswithin the sodiumpotassiumpump. Our
functional analyses reinforce the association between ATP1A2 muta-
tions and sporadic and familial hemiplegic migraine, but do not pro-
vide robust functional evidence for a relationship with other types of
migraine.
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2.1. The Gateway system
The wild type and mutants of Na,K-ATPase α2 were cloned by
Gateway-adapted PCR procedures according to the manufacturer's in-
structions (Invitrogen, Breda, The Netherlands). A destination vector
was generated by subcloning the cDNA of the human Na,K-ATPase
β1-subunit in the pFastBac Dual vector (Life Technologies, Breda,
The Netherlands) after the p10 promotor and the α2 subunit in the
Gateway Reading Frame Cassette B (Invitrogen) that was introduced
after the polyhedrin promoter. The (mutated) entry vectors were
recombined with this vector by using Gateway LR Clonase II Enzyme
Mix (Invitrogen).
Site-directedmutagenesis was performed using the Single Base mu-
tation system, DpnI method (Stratagene, La Jolla, CA). The mutagenic
primer (Biolegio, Nijmegen, The Netherlands) introduced the desired
mutation in the α-subunit. After selection the mutants were checked
by Sanger direct sequence analysis.
2.2. Generation of recombinant viruses
The pFastBac Dual transfer vector containing the different (mutant)
cDNAs was transformed to competent DH10bac Escherichia coli cells
(Life Technologies) harboring the baculovirus genome (bacmid) and a
transposition helper vector. Upon transposition between the Tn7 sites
in the transfer vector and the bacmid, recombinant bacmids were se-
lected and isolated [8]. Subsequently, insect Sf9 cells were transfected
with recombinant bacmids using Cellfectin reagent (Life Technologies).
After a three-day incubation period, recombinant baculoviruses were
isolated and used to infect Sf9 cells at a multiplicity of infection of 0.1.
Four days after infection, the ampliﬁed viruses were harvested.
2.3. Preparation of Sf9 membranes
Sf9 cells were grown at 27 °C in 175 cm2 monolayers and later
in 500-mL shaking ﬂasks cultures. For production of Na,K-ATPase,
1.5.106 cells·mL−1 were infected at a multiplicity of infection of
1–3 in the presence of 1% (v/v) ethanol, and 0.1% (w/v) Pluronic
F-68 (Sigma, Bornem, Belgium) in Xpress medium (BioWhittaker,
Walkersville, MD) as described before [9]. After 3 days, the Sf9 cells
were harvested by centrifugation at 2000 ×g for 5 min. The cells were
resuspended at 0 °C in 0.25 M sucrose, 2 mM EDTA, and 25 mM
Hepes/Tris (pH 7.0), and sonicated for 30 s at 60 W (Branson
Power Company, Denbury, CT). After centrifugation for 30 min at
10,000 ×g the supernatant was collected and centrifuged again
for 60 min at 100,000 ×g at 4 °C. The pelleted membranes were
resuspended in the above-mentioned buffer and stored at−20 °C and
the protein concentration was determined with the modiﬁed Lowry
method.
2.4. Western blotting
Protein samples from the membrane fraction were solubilized in
SDS-PAGE sample buffer and separated on SDS-gels containing 10% acryl-
amide as described previously [10]. For immunoblotting, the separated
proteins were transferred to Immobilon polyvinylideneﬂuoride mem-
branes (Millipore Corporation, Bedford, MA). The α-subunit of the Na,
K-ATPase was detected with the polyclonal antibody C356-M09 [10].
2.5. Na,K-ATPase assay
The ouabain sensitive ATPase activity was determined using a radio-
chemical method [11]. For this purpose, 0.6–5 μg of Sf9 membranes
were added to 100 μL of medium, which contained 10–200 μM [γ-32P]-
ATP (speciﬁc activity 20–100 mCi·mmol−1), 1.2 mM MgCl2, 0.2 mMEGTA, 0.1 mM EDTA, 0.1 mM ouabain, 1 mM Tris–N3, 25 mM Tris–HCl
(pH 7.0) and various concentrations of KCl and NaCl in the presence
and absence of 0.1 mM ouabain. After incubation for 30 min at 37 °C, the
reactionwas stopped by adding 500 μL 10% (w/v) charcoal in 6% (v/v) tri-
chloroacetic acid and after 10 min at 0 °C themixturewas centrifuged for
10 s (10,000 ×g). To 0.15 mL of the clear supernatant, containing the
liberated inorganic phosphate (32Pi), 3 mL OptiFluor (Canberra Packard,
Tilburg, The Netherlands) was added and the mixture was analyzed by
liquid scintillation analysis. In general, blanks were prepared by incubat-
ing in the absence of membranes. The Na,K-ATPase activity is presented
as the difference of the activity in the absence and presence of ouabain.2.6. Ouabain binding capacity
Ouabain bindingwas determined as described before [12]. Sf9mem-
branes (100 μg) were incubated at 21 °C in 20 mM histidine (pH 7.0),
and 5.0 mM MgCl2 and 5.0 mM Pi in a volume of 50 μL. 10 μL of [3H]-
ouabain (speciﬁc activity 30 Ci·mmol−1, Perkin Elmer) was added and
the mixture was incubated for 2 h at 21 °C. The protein was collected
by ﬁltration over a 0.8-μm membrane ﬁlter (Schleicher and Schuell,
Dassel, Germany). Afterwashing twicewith 2 mLwater (4 °C), the ﬁlters
were analyzed by liquid scintillation analysis. Data are corrected for the
levels of nonspeciﬁc ouabain binding obtained with mock-infected
membranes.2.7. Chemicals
Cellfectin, competent DH10bac E. coli cells and all enzymes used for
DNA cloningwere purchased from Invitrogen (Breda, The Netherlands).
[γ-32P]ATP (3000 Ci·mmol−1) was obtained from Perkin-Elmer
(Waltham, MA, USA).2.8. Analysis of data
All data are presented as mean values for three individual enzyme
preparations with standard error of the mean. Differences were tested
for signiﬁcance by means of the Student's t-test. IC50 and K0.5 values
were determined by analyzing the plots using the Non-Linear Curve
Fitting program (Hill equation function) of Origin 6.1 (Microcal,
Northampton, MA).
The Na+0.5 and K+0.5 values were calculated via the Hill equation in
Origin, on the averaged data with standard error of the mean. The Hill
coefﬁcient value obtained for the wild type Na,K-ATPase (1.73 for Na+
and 1.3 for K+) was also used for the mutants studied. The maximal
ATPase activity (Vmax) is the activity in the presence of 50 mM NaCl,
5 mM KCl, 1 mMMgCl2 and 0.1 mM ATP at pH 7.0.2.9. Molecular modeling
The consequences of the mutations studied can be interpreted by
studying the location and interactions of the speciﬁc amino acid in the
sodium pump structures. The role of the amino acids can be understood
better when its role during the catalytic cycle is visualized. Therefore,
we made homology models of the human sodium pump in different
conformations using SERCA and pig and shark Na,K-ATPase as a
template. E1Na+ (2C9M), E1Na+-ATP (1T5S), E1Na+-P-ADP (1T5T),
E1Na+P:ADP (3BA6), E2P (3N23), E2K+-P ATP (3B9R), E2K+-Pi ATP
(2ZXE), E2K+ ATP (2C88). The homology model was built with the
YASARA and WHAT IF Twinset using default parameters. YASARA
calculated “Z-scores” where used for validation and selection of the
best model. Minimization was done with the standard force ﬁeld in
YASARA [9].
Fig. 1. Expression of wild type and mutant Na,K-ATPase. A: Western blot of the different
Na,K-ATPase membrane preparations (10 μg) isolated from infected Sf9 cells. The pres-
ence of Na,K-ATPase α-subunit was detected with antibody C356-M09 [10]. B: Ouabain
binding to wild type and mutant Na,K-ATPases. The assay was performed at 21 °C in
20 mMhistidine buffer (pH 7.0), 5.0 mMMgCl2, 5 mMPi and 12 nM3H-ouabain. Average
with SE for 3 different expression experiments.
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3.1. Functional expression of ATP1A2 migraine mutants in insect cells
We selected 11 ATP1A2mutations that were located in different do-
mains of the α2 subunit of the Na,K-ATPase enzyme. All mutations had
been identiﬁed in clinical genetic studies and postulated as disease-
causing. A PCR-based mutagenesis method was used to introduce the
respective mutations in the human ATP1A2 cDNA. The (mutant)
Na,K-ATPase α2 and β1 subunit were cloned into recombinant
baculoviruses and expressed in Sf9 insect cells. Themembrane fractions
of cells expressing the recombinant ATPase proteins were isolated.
Western blot analysis revealed similar expression levels for mutant
and wild type Na,K-ATPase protein (Fig. 1).
The immunological detection of proteins onWestern blots does, how-
ever, not indicate whether the expressed proteins are functionally active.
To investigate functionality of themutant proteins, we performed several
functional assays. For instance, binding of the Na,K-ATPase inhibitor oua-
bain in a pocket of the enzyme close to the cation binding sites indicates
that the protein is able to adopt a conformation that binds ouabain
[9,13,14]. The ouabain equilibrium saturationwas analyzed and the afﬁn-
ity for ouabain was similar for all mutants (S1). However, the maximum
binding (EOmax) varied between the different mutants (Table 1). The
maximum binding of the wild type and Y9N, R51H, E174K, R548C,
and R548H varied between 2.5 and 3.6 pmol/mg and the binding ofTable 1
Summary of the catalytic properties of wild type and mutant Na,K-ATPase from supplementar
values of the mutant enzyme preparations are compared to those of the wild type.
Max ouabain
pmol/mg protein
Ouabain afﬁnity
nM
ATPase activity
μmol/mg protein/h
wt 3.15 ± 0.40 18.6 ± 2.9 0.55 ± 0.10
Y9N 2.67 ± 0.45 16.5 ± 2.0 0.50 ± 0.12
R51H 3.58 ± 0.87 18.5 ± 3.4 0.65 ± 0.13
E174K 2.66 ± 0.65 19.7 ± 4.5 0.27 ± 0.07
R548C 2.87 ± 0.41 21.6 ± 1.8 0.12 ± 0.04⁎⁎
R548H 2.46 ± 0.11 21.5 ± 1.9 0.17 ± 0.02⁎
E700K 0.75 ± 0.06⁎⁎⁎ 19.4 ± 1.9 0.06 ± 0.01⁎⁎
C702Y 1.61 ± 0.25⁎ 14.8 ± 1.4 0.26 ± 0.04⁎
P786L n.d. n.d. −0.01 ± 0.00⁎⁎
R879Q 1.77 ± 0.26⁎ 16.4 ± 2.0 0.35 ± 0.08
G900R 0.75 ± 0.15⁎⁎ 11.8 ± 1.1 0.16 ± 0.04⁎
E902K 0.76 ± 0.08⁎⁎ 12.6 ± 2.5 0.18 ± 0.04⁎
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.005.C702Y and R879Q varied between 1.6 and 1.8 pmol/mg. In contrast,
themaximumbinding of E700K, G900R, and E902Kwas greatly reduced
(approximately 0.8 pmol/mg), whereas P786L was not able to bind
ouabain at all. This indicates that although none of themutations affect-
ed the expression levels, four mutations (i.e. E700K, P786L, G900R, and
E902K) seriously inﬂuence functional expression.
3.2. Kinetic alterations
One of the most important properties of the Na,K-ATPase that could
be inﬂuenced by mutations is substrate afﬁnity. In previous studies by
Segall et al. [15,16] threemutations (T345A, R689Q, andM731T) showed
an affected K+ and vanadate afﬁnity. In addition, Tavraz et al. [17,18]
showed that somemutants possessed altered K+ afﬁnities. To investigate
whether the 11 mutants exhibit kinetic alterations, we determined Na+,
K+, and ATP afﬁnities for the wild type and mutant enzymes.
The Na,K-ATPase activity was determined in the presence of 100 μM
ATP, 5 mM KCl and varying concentrations of NaCl (S2). The apparent
afﬁnities for Na+ are depicted in Table 1 and were not signiﬁcantly dif-
ferent for Y9N, R51H, C702Y, R879Q, G900R and E902Kwhen compared
to wild type enzyme. The ATPase activity of E700K and P786L was not
sufﬁcient to obtain reliable ATPase activities under different circum-
stances. E174K, R548C, and R548H, however, had a reduced apparent
Na+ afﬁnity (15.7, 17.0, and 13.8 mM, respectively) compared to wild
type enzyme (7.1 mM). In Fig. 2 the apparent afﬁnity for Na+ of the
R548C mutant and wild type are shown.
In the presence of 100 μMATP, 50 mMNaCl and varying concentra-
tions of KCl, the activity of Na,K-ATPase was determined (S3). The ap-
parent K+ afﬁnity of Y9N, R51H, E174K, C702Y, R879Q, G900R and
E902Kwas not signiﬁcantly changed compared to thewild type enzyme
(Table 1). R548C and R548H, however, had an increased apparentK+ af-
ﬁnity (0.81 and 0.45 mM, respectively) compared to wild type enzyme
(1.35 mM).
The apparent ATP afﬁnity in the presence of 50 mMNaCl and 5 mM
KCl was similar for all mutants and the wild type enzyme (Table 1 and
S4). We determined the maximal ATPase activity at 0.1 mM ATP,
50 mM NaCl and 5 mM KCl (S4, Table 1). Mutants Y9N and R51H had
a similar Vmax as wild type enzyme. E174K, C702Y, and R879Q had a
somewhat reduced Vmax (47–64%), whereas the activities of R548C,
R548H, E900R, and E902K were greatly reduced (22–33%). The P786L
was completely inactive and the activity of E700K was only 11% of
that of wild type enzyme.
The catalytic turnover determined as the ratio of Vmax/EOmax is
plotted in Fig. 3 and the calculated values are shown in Table 1. Most
mutants had a similar turnover number as wild type enzyme. They Figs. S1–S4. The values presented are the mean ± SE of 3–4 enzyme preparations. The
Na+ afﬁnity
mM
K+ afﬁnity
mM
ATP afﬁnity
μM
Turnover
(min−1)
7.1 ± 0.47 1.35 ± 0.15 25.0 ± 4.2 3032 ± 637
8.1 ± 0.97 1.54 ± 0.14 23.3 ± 6.1 3110 ± 362
7.6 ± 0.73 1.33 ± 0.14 26.0 ± 2.3 3229 ± 652
15.7 ± 2.38⁎ 0.86 ± 0.18 29.8 ± 5.5 1755 ± 270
17.0 ± 2.22⁎⁎ 0.81 ± 0.13⁎ 31.3 ± 6.9 713 ± 200⁎
13.8 ± 0.59⁎⁎⁎ 0.45 ± 0.05⁎⁎ 23.0 ± 10.2 1160 ± 168⁎
n.d. n.d. n.d. 1449 ± 318
6.2 ± 1.07 1.17 ± 0.15 36.9 ± 8.3 2827 ± 405
n.d. n.d. n.d. n.d.
8.5 ± 0.76 1.43 ± 0.14 35.2 ± 5.9 3593 ± 948
7.8 ± 2.18 1.26 ± 0.16 29.7 ± 5.7 3854 ± 875
10.8 ± 1.58 1.23 ± 0.15 42.6 ± 4.6⁎ 4873 ± 1657
Fig. 2. The properties of the wild type Na,K-ATPase and the R548C mutant. Na+ dependence (A), K+ dependence (B), and ATP dependence (Scatchard plot) (C) are shown in the ATPase
activity assay. In panel D the ouabain binding afﬁnity and capacity are shown in a Scatchard plot. The assay conditions were described in the Materials and methods section.
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signiﬁcantly decreased when compared to wild type. In contrast, the
turnover numbers of R548C and R548H were signiﬁcantly reduced. Al-
though their ouabain binding level was comparable to that of wild
type, their Na,K-ATPase activity was largely reduced.Fig. 3. Relationship between Na,K-ATPase activity and ouabain binding. Themaximal oua-
bain binding (pmol per mg protein) and the Na,K-ATPase activities (μmol ATP hydrolyzed
per mg protein per h) as determined from Supplementary Figs. 1 and 4 were plotted for
eachmutant and wild type enzyme. The dotted line indicates a catalytic turnover number
that is equal to that of the wild type enzyme.4. Discussion
Familial hemiplegic migraine type 2 (FHM2) is caused by mutations
in ATP1A2 that encodes theα2 subunit of Na,K-ATPase. Here we studied
the catalytic function of 11 Na,K-ATPase mutants that were not func-
tionally characterized (in detail) before. For several of these mutants,
we predicted that the domain interactions of the α2 subunit were
disrupted, which suggested a novel pathogenic mechanism for Na,
K-ATPase dysfunction in relation to migraine. The identiﬁed functional
consequences of the ATP1A2 mutants will be discussed below grouped
by domain.
Within the A-domain we investigated mutant E174K. The negative
charge at residue 174 is highly conserved in PIIc-type ATPases. In a pre-
vious study the E174Kmutation had been characterized to some extent,
and showed no difference from the wild type α2 subunit, suggesting
perhaps a more subtle effect on protein function than revealed by the
activity assay used [19]. Our functional studies show a slightly reduced
catalytic turnover, a clearly reduced apparent Na+ afﬁnity, and an in-
creased apparent K+ afﬁnity compared to that of wild type enzyme. In
the A domain Glu174 is predicted to be exposed to the cytosol in most
conformations. However, in the E1P conformation Glu174 is predicted
to be in close proximity to Lys432 in theN-domain (Fig. 4). In this confor-
mation a salt bridge between both residuesmight stabilize the E1P sodi-
um binding conformation. Substitution of the negatively charged Glu
with the positively charged Lys will likely disrupt this stabilizing inter-
action and could thereby be responsible for the reduced apparent Na+
afﬁnity by decreasing its association rate or increasing its dissociation
rate.
Several of the studied ATP1A2 mutations are located in the N do-
main. For this studywe focused onmutants R548C and R548H. Arginine
548 is strongly conserved in P-type ATPases. It most likely forms a salt
bridge with Glu221 that stabilizes the interaction between the A and N
Fig. 4. Interaction between E174 and K432 visualized in Na,K-ATPase in the E1P conforma-
tion (homology model based on 3BA6) and E2K·Pi state (2ZXE). View is from outside to
inside. Cyan is transmembrane domain; blue is phosphorylation domain, red is nucleotide-
binding domain; green is actuator domain.
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bound, Arg548 probably forms a salt bridge to the β-phosphate of ATP.
Indeed, the substitution of Arg548 with Gln was shown to abolish high-
afﬁnity ATP binding andNa,K-ATPase activity [21], whereas substitution
with Lys was shown not to affect ATP binding, but reduced ATPaseFig. 5. Interaction between R548 and E221 visualized in the crystal structure of Na,
K-ATPase in the E1 conformation (homologymodel based on2C9M) andE2K·Pi state (2ZXE).
Cyan is transmembrane domain; blue is phosphorylation domain, red is nucleotide-binding
domain; green is actuator domain.activity to 30% of the wild type enzyme [21]. Nucleotides might disrupt
theArg548–Glu221 salt bridge, aiding dissociation of theA andNdomains
and accelerating K+ release [20]. In the E1 conformation the A and N do-
mains are far apart and the salt bridge between Arg548 and Glu221 is ab-
sent (Fig. 5). In our functional studies we observed that both R548C and
R548H had a reduced catalytic turnover number, a slightly reduced Na+
afﬁnity and an increased K+ afﬁnity. Interestingly, the replacement of
arginine by cysteine removes the salt bridge between the N and A do-
mains, due towhich binding of K+might be facilitated. In R548H similar
effects were observed, suggesting that also in this case a salt bridge can-
not be formed.
Within the Na,K-ATPase P domain we analyzed mutant E700K. Our
functional studies showed no detectable changes in apparent Na+, K+,
or ATP afﬁnities. However, the number of active E700K transportermol-
ecules is signiﬁcantly decreased compared to wild type, supporting a
causal relationwith disease for thismutation. Glu700 is highly conserved
in P type IIc ATPases and located at the surface of the P-domain,where it
might be involved in the formation of a salt bridge with Lys35 of the
A-domain in the E2K·Pi conformation (Fig. 6). Recently, it was shown
that E700K exhibits a reduced rate of E2P dephosphorylation and a re-
duced vanadate afﬁnity [22]. These observations are in agreement with
our observed reduced activity.Moreover, the disruption of the salt bridge
might destabilize the E2P conformation and thereby inhibit the E1P to E2P
transition. In contrast to Schack et al. (2012), we did not observe an in-
creased ouabain afﬁnity.
The P786L mutation is located within the transmembrane (TM) do-
main, more speciﬁcally TM5. P786L previously did not show survival of
cells in our specialized assay [23]. Our present functional studies showed
no ouabain binding or ATPase activity for this mutant. In the sarcoplas-
mic reticulum Ca2+-ATPase substitution of the corresponding amino
acid Cys774 with alanine caused inhibition of Ca2+ transport and ATPase
activity [24]. This cysteine has been proposed to play a central role in
proton transfer [25]. Homology modeling studies suggested that Pro786
in M5 might be necessary for the Na+ ions to reach their binding site.
This might be the reason why M5 possesses the sequence PEITP, similarFig. 6. Possible interaction between E700 and K35 visualized in the crystal structure of Na,
K-ATPase in the E1 conformation (homology model based on 2C9M) and E2K·Pi state
(2ZXE). K35 is located at theN-terminal region of Na,K-ATPase, due towhich themodeling
is rather hypothetical. View is from outside to inside. Cyan is transmembrane domain;
blue is phosphorylation domain, red is nucleotide-binding domain; green is actuator
domain.
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sponsible for the very inefﬁcient signal anchor sequence [27]. Its correct
membrane insertion is probably mediated by posttranslational hairpin
formation with M6, which is favored by a proline pair in the connecting
loop. The prolinemutant had a decreased apparent Na+ and K+ afﬁnities
and a reduced turnover, whereaswe did not observe any ATPase activity.
The discrepancy ismost likely due to the expression of Xenopus laevisNa,
K-ATPase in X. laevis oocytes at 18 °C [27], whereaswe expressed human
Na,K-ATPase in insect cells at 27 °C. Previously, it was demonstrated that
folding defects of mutant proteins can be revealed in a temperature-
dependent fashion [17].
Several studied ATP1A2 mutations are located in the extracellular
loop between transmembrane segment 7 and 8: R879Q [28], R879W
[28], W887R [6], G900R [29], E902K [30], and R908Q [23]. This part of
the Na,K-ATPase α-subunit has been implicated in binding of the Na,
K-ATPase β-subunit [31,32]. We did not observe any effect on ligand af-
ﬁnity for theG900R and E902Kmutants, althoughwe observed a drastic
reduction in the amount of functional ATPase molecules for these mu-
tants. The overall effect for the patient will likely be that the amount
of functional Na,K-ATPase molecules is reduced, which may hamper
the restoring of ions and might enhance cortical spreading depression.
The affected glycine 900 is conserved and part of the amino acid se-
quence SYGQ, which is directly involved in interactions between the
α- and β-subunits of the Na, K-ATPase [32]. Glycine does not carry a
side chain and therefore is important for the position of neighboring
amino acids. The crystal structures of Na,K-ATPase indeed show that
in this region several hydrogen bonds between both subunits are likely
[20,33]. For instance, Tyr899 binds to Lys250 andGln901 binds to the back-
bone atoms of Ile185 (Fig. 7) [20,33]. Glutamic acid 902 is also well
conserved (Asn or Glu) and forms a hydrogen bond with Arg183 of the
β-subunit. Replacement of Gly900 or Glu902 will likely disrupt hydrogen
bridges and affect the interaction between theα- and β-subunits of the
Na, K-ATPase enzyme. Due to these mutations, the formation of anα–β
enzyme complex is predicted to be hampered. However, if the α and β
subunits were able to form a functional complex, its functional proper-
ties were not affected.
The R879Q mutant showed Na+ K+, ATP and ouabain afﬁnities that
are similar to that of thewild type enzyme.Moreover, the number of ac-
tive R879Q transporter molecules was not signiﬁcantly decreased com-
pared to the wild type. This non-conserved Arginine is located in the
ﬁrst half of the extracellular 7–8 loop, that most likely is not involved
in direct binding of the beta subunit [31]. Y9N and R51H are both locat-
ed in the Na,K-ATPase N-terminus and did not show any functional dif-
ferences. Functional studies also showed no difference in apparent Na+,
K+, or ATP afﬁnities of C702Y compared towild type enzyme.Moreover,
the number of active C702Y transporter molecules was, at best, onlyFig. 7. Interaction between Na,K-ATPase α and β subunits visualized in the crystal struc-
ture of Na,K-ATPase in the E2K·Pi state (2ZXE). Cyan is transmembrane domain of the α
subunit; magenta is β subunit.slightly decreased compared to wild type enzyme. A cysteine-less Na,
K-ATPase α1 subunit in which all 23 cysteines were replaced by serine
residues still possessed the same catalytic turnover number and only
minor changes inNa+ andK+ afﬁnitieswere observed [34]. Thenumber
of active cysteine-less Na,K-ATPasemoleculeswas still 30% of that of the
wild type. Thus, the Na,K-ATPaseα1 subunit seems to contain no cyste-
ine residues that are essential for its function which is in line with our
ﬁnding that the single C702Y mutation did not affect Na,K-ATPase
α2β1 function. This observation, therefore, casts considerable doubt
on whether this mutant caused disease in the patient.
Our functional studies provide important experimental evidence as
to which ATP1A2 mutations are likely disease-causing or not. For the
three typical FHM2 families with mutations R548C, E700K and E902K
that were absent in healthy relatives and large subsets of control chro-
mosomes [30,35,36], we could clearly show catalytic dysfunction of
the Na,K-ATPase enzyme. The same is true for mutation G900R, that
was observed in a family with patients having FHM, epileptic seizures
or both [29], indicating that the mutation may underlie both pheno-
types. We showed that the functional consequences of G900R are com-
parable with those of E902K. Another substitution of Arg548 (R548H)
was found in an Italian family that was reported suffering from basilar
migraine and absent from a large group of controls [37]. Both Arg548
mutations resulted in similar functional effects and are likely disease-
causing. The difference between FHM and basilar migraine could be
due to the minor difference in apparent K+ afﬁnities, yet undiscovered
differences in genetic background, or perhaps diagnosing an atypical
case of FHM as basilar migraine.
The ATP1A2 P786L variant was identiﬁed in a family with sporadic
hemiplegic migraine (SHM) without additional associated neurologic
symptoms like cerebellar ataxia or epilepsy [23]. The P786L mutation
had occurred de novo as it was not present in the proband's parents
and false paternity was excluded. P786L completely disrupted the cata-
lytic activity of Na,K-ATPase.
E174K was found in a family in which several members suffered
from migraine with aura, whereas the mutation was not observed in
520 control chromosomes [19]. The high degree of conservation of
this negative charge and the ﬁnding that the kinetic properties of Na,
K-ATPase are affected provide some evidence that E174K may be in-
volved in causing the migraine phenotype and is not merely a rare
non-causal polymorphism. Still, as the mutation was also present in
the unaffected maternal grandfather, the functional effects of E174K
appear not sufﬁcient to cause the migraine phenotype.
In contrast to the disease-causing ATP1A2mutants described above,
we observed no or only very minimal catalytic effects for mutants
R879Q, C702Y, Y9N and R51H. Of them, R879Qwas identiﬁed in a Danish
nationwide search of SHM patients [28]. It was not detected in the 92
controls and was found in several unaffected family members [28].
C702Y occurred in a family with occipitotemporal epilepsy and mi-
graine without aura and was present in four unaffected individuals
and absent in 170 control individuals [29]. Y9N was identiﬁed in two
SHM patients and the healthy mother of one of the probands [28,38].
Moreover, Y9N has been observed in the unaffected mother of a carrier
with the R583Q mutation [28]. Finally, a Portuguese three-generation
family with migraine without aura harbored the R51H variant [39].
R51H was not present in 346 control chromosomes and seemed to co-
segregate reasonably well with migraine without aura in the proband's
nuclear family. Cell survival assays [39] and the present study, however,
fail to provide any evidence for a functional consequence of this variant.
The absence of functional abnormalities in this study suggests that
R879Q, C702Y, Y9N and R51H for the moment should be regarded as
rare missense variants without a clear pathogenic effect.
In conclusion, in this study, we analyzed 11 mutations in the Na,
K-ATPase α2 subunit that have been reported in patients with various
migraine phenotypes. Four FHM mutations (R548C, E700K, G900R,
E902K) and one SHM mutation (P786L) clearly affected Na,K-ATPase
pump function and must be regarded as disease-causing. Most of
2179H.G.P. Swarts et al. / Biochimica et Biophysica Acta 1832 (2013) 2173–2179them probably hamper the interactions between Na,K-ATPase domains
during the catalytic cycle. Of the non-hemiplegic migraine mutations,
E174K (migraine with aura) and R548H (basilar migraine) affected
Na,K-ATPase pump function aswell. No functional effects were, howev-
er, observed for SHM mutations Y9N, P786L, and R879Q and for R51H
and C702Y that were found in patients with migraine with or without
aura. Our current results strengthen the role of ATP1A2 mutations in
FHM2 and SHM.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.08.003.
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